SEC filings
ResMed| (RMD)
Recent filings ResMed| made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000943819All filings on SEC.gov
10-QQuarterly report
Quarterly report
ResMed reported first-quarter fiscal 2027 net revenue of $1.4 billion, up 6% year over year, with gross margin of 61.5% and diluted EPS of $2.92 versus $2.37 a year earlier. …
8-KCurrent report
Results of Operations and Financial Condition; Other Events
ResMed reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% (7% on a core constant currency basis), with GAAP diluted earnings per share of $2.92, up 23%, and non-GAAP diluted EPS of $2.91, up 14%, while reiterating fiscal…
8-KCurrent report
Other Events
ResMed Inc. entered into an accelerated share repurchase agreement with Citibank, N.A. on August 31, 2026 to repurchase $450.0 million of its common stock, using proceeds from the sale of its MatrixCare business and cash on hand. …
8-KCurrent report
Changes in Registrant's Certifying Accountant; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers …
ResMed dismissed KPMG as its independent registered public accounting firm effective Aug. 13, 2026, and appointed PricewaterhouseCoopers to the role for the fiscal year ending June 30, 2027, subject to PricewaterhouseCoopers’ standard…
10-KAnnual report
Annual report
ResMed reported fiscal 2026 net revenue of $5.65 billion, up 10% from $5.15 billion a year earlier, and net income of $1.52 billion, or $10.43 per diluted share. …
8-KCurrent report
Results of Operations and Financial Condition; Other Events
ResMed reported fourth-quarter revenue up 9% to a record $1.5 billion and fiscal year 2026 revenue up 10% to $5.7 billion, and its board declared a quarterly dividend of $0.66 per share, a 10% increase. …
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow ResMed| in Readster
Add ResMed| to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.